DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
PRCT logo

PROCEPT BioRobotics Corporation Stock Price

NasdaqGM:PRCT Community·US$1.1b Market Cap
  • 4 Narratives written by author
  • 2 Comments on narratives written by author
  • 49 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

PRCT Share Price Performance

US$18.51
-19.95 (-51.87%)
​
US$22.73
Fair Value
US$18.51
-19.95 (-51.87%)
18.6% undervalued intrinsic discount
US$22.73
Fair Value
Price US$18.51
AnalystConsensusTarget US$22.73
Betsareoff US$25.26
AnalystLowTarget US$16.00
Thu, 6 Aug 26
Fair ValueUS$22.73
Share Pricen/a

PRCT Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$22.73 18.6% undervalued intrinsic discount

PRCT: Share Price Will Likely React Sharply To Upcoming Earnings Data

1users have liked this narrative
0users have commented on this narrative
27users have followed this narrative
BE
Betsareoff's
Fair Value
·
Fair Value US$25.26 26.7% undervalued intrinsic discount

PROCEPT BioRobotics sees 17.69% revenue growth and aims for 12.94% profit margin

0users have liked this narrative
1users have commented on this narrative
6users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$16 15.7% overvalued intrinsic discount

Competitive Pressures Will Hinder Urologic Procedures Yet Spur Progress

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
PRCT logo
PROCEPT BioRobotics
26.7% undervalued intrinsic discount

PROCEPT BioRobotics sees 17.69% revenue growth and aims for 12.94% profit margin

View narrative
BE
Betsareoff
Updated 30 Jul
Read Narrative
PRCT logo
PROCEPT BioRobotics
18.6% undervalued intrinsic discount

PRCT: Share Price Will Likely React Sharply To Upcoming Earnings Data

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 6 Aug
Read Narrative
PRCT logo
PROCEPT BioRobotics
33.9% undervalued intrinsic discount

Aging Population And Robotic Advances Will Unlock Urologic Potential

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 3 Sep
Read Narrative
PRCT logo
PROCEPT BioRobotics
15.7% overvalued intrinsic discount

Competitive Pressures Will Hinder Urologic Procedures Yet Spur Progress

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 20 Aug
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

BE
PRCT logo

PROCEPT BioRobotics sees 17.69% revenue growth and aims for 12.94% profit margin

Fair Value: US$25.26 26.7% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
PRCT logo

PRCT: Future Trial Results Will Drive Long Term Upside Potential

Fair Value: US$28 33.9% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
PRCT logo

PRCT: Excess Handpiece Inventory And Litigation Will Constrain Future Upside

Fair Value: US$16 15.7% overvalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Excellent balance sheet and slightly overvalued.

1 Risk
1 Reward
View Full Analysis

PROCEPT BioRobotics Corporation Key Details

US$337.3m

Revenue

US$123.6m

Cost of Revenue

US$213.7m

Gross Profit

US$323.5m

Other Expenses

-US$109.8m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-1.92
63.36%
-32.54%
15.2%
View Full Analysis

About PRCT

Founded
2007
Employees
888
CEO
Larry Wood
WebsiteView website
www.procept-biorobotics.com

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Recent PRCT News & Updates

User avatar
Narrative Update • Sep 03

PRCT: Future Trial Results Will Drive Long Term Upside Potential

Analysts have reduced the fair value estimate on PROCEPT BioRobotics to $28 from $37, aligning with recent price target cuts into the $20 range and updated models that reflect slower procedure and demand trends, as well as a lower future P/E assumption. Analyst Commentary Recent research on PROCEPT BioRobotics points to a more cautious stance from several firms, with multiple downgrades and lower price targets clustered in the US$20 range.
User avatar
Narrative Update • Aug 20

PRCT: Excess Handpiece Inventory And Litigation Will Constrain Future Upside

Analysts have reduced their fair value estimate for Procept BioRobotics from about $20.24 to $16.00. This change reflects lower price targets and more cautious assumptions on revenue growth and valuation multiples following recent research updates.

Recent updates

No updates

PROCEPT BioRobotics Corporation Competitors

LNTH logo

Lantheus Holdings

Symbol: NasdaqGM:LNTH
Market cap: US$6.6b
CHE logo

Chemed

Symbol: NYSE:CHE
Market cap: US$6.6b
HIMS logo

Hims & Hers Health

Symbol: NYSE:HIMS
Market cap: US$6.5b
MMED logo

MiniMed Group

Symbol: NasdaqGS:MMED
Market cap: US$6.1b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide